Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: Randomised study within organised screening programme

BMJ (Online)

Volumn 340, Issue 7754, 2010, Pages 1014-

  Anttila, Ahti ^a   Kotaniemi Talonen, Laura ^a   Leinonen, Maarit ^a   Hakama, Matti ^a   Laurila, Pekka ^b   Tarkkanen, Jussi ^b   Malila, Nea ^a,c   Nieminen, Pekka ^b,d  

^a FINNISH CANCER REGISTRY   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

^d Cancer Society of Finland   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARM; ARTICLE; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER REGISTRY; CANCER SCREENING; CERVICAL ADENOCARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DNA SCREENING; FEMALE; FINLAND; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADENOCARCINOMA; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOLOGICAL TECHNIQUES; DNA PROBES; DNA, VIRAL; FEMALE; FINLAND; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS;

EID: 77953924273     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c1804     Document Type: Article

References (20)

1. Screening for cancer of the uterine cervix. From the IARC working group on cervical cancer screening and the UICC project group on the evaluation of screening programmes for cancer. IARC Sci Publ 1986;76:1-315.
2. International Agency for Research on Cancer. IARC/WHO handbooks of cancer prevention. Vol 10: cervix cancer screening. IARC Press, 2005.
3. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Vol 90: human papillomaviruses. IARC Press, 2007.
4. Arbyn M, Dillner J, Schenck U, Nieminen P,Weiderpass E, Da Silva JD, et al. Methods for screening and diagnosis. In: Arbyn M, Anttila A, Jordan J, Ronco G, Segnan N, Wiener HG, eds. European guidelines for quality assurance in cervical cancer screening. 2nd ed. Office for Official Publications of the European Communities, 2008.
5. Van Oortmarssen GJ, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991;64:559-65.
6. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
7. Bulkmans NWJ, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJP, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72.
8. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97.
9. Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;377:a1754.
10. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-94.
11. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomized setting. Br J Cancer 2005;93:862-7.
12. Anttila A, Hakama M, Kotaniemi-Talonen L, Nieminen P. Alternative technologies in cervical cancer screening: a randomised evaluation trial. BMC Public Health 2006;6:252.
13. Kotaniemi-Talonen L, Anttila A, Malila N, Tarkkanen J, Laurila P, Hakama M, et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008;44:565-71.
14. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Hakama M, Tarkkanen J, et al. Age-specific performance of cervical cancer screening with primary HPV DNA test compared to conventional cytological screening in a randomised setting. J Natl Cancer Inst 2009;101:1612-23.
15. Anttila A, Nieminen P. Cervical cancer screening programme in Finland. Eur J Cancer 2000;36:2209-14.
16. Monto K, Nieminen P. Gynekologisten irtosolunäytteiden määrät ja raportointitavat Suomessa [Finnish]. Suomen Lääkärilehti 2005;60:2093-7.
17. Finnish Cancer Registry-Institute for Statistical and Epidemiological Cancer Research. Cancer in Finland 2006 and 2007. Cancer Statistics of the National Institute for Health and Welfare (THL). Cancer Society of Finland Publication No. 76, Helsinki 2009.
18. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100:492-501.
19. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10:672-82.
20. Leinonen M, Kotaniemi-Talonen L, Anttila A, Dyba T, Tarkkanen J, Nieminen P. Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int J Cancer 2008;123:1344-9.